Zenagamtide has controlled Phase 2 human trials showing effects on blood sugar and body weight. Phase 3 weight-management studies are now underway, but it remains investigational and is not an approved medicine.
Still uncertain: Marketing approval, long-term cardiovascular outcomes, rare-event safety and final therapeutic dosing.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
Unimolecular GLP-1, amylin and calcitonin receptor agonist peptide
Entity type
Peptide
Research focus
Obesity, type 2 diabetes, sleep apnoea, knee osteoarthritis, heart failure
Human evidence
Two peer-reviewed 2026 Phase II trials show significant HbA1c reductions with subcutaneous and oral zenagamtide in type 2 diabetes; Phase 3 weight-management development is underway.
Regulatory status
Investigational; Phase 3 obesity programme initiated in 2026. No general marketing authorisation identified.
Main limitations
Marketing approval, long-term cardiovascular outcomes, rare-event safety or final therapeutic dosing.
Safety
GI tolerability is the main recurring signal; early-phase attrition and formulation differences must be visible.
Evidence reviewed
2026-09-18
i
Two peer-reviewed 2026 Phase II trials show significant HbA1c reductions with subcutaneous and oral zenagamtide in type 2 diabetes; Phase 3 weight-management development is underway.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
GI tolerability is the main recurring signal; early-phase attrition and formulation differences must be visible.
Gastrointestinal events are frequent and mostly mild-to-moderate in early trials; early studies also had substantial participant withdrawal, requiring cautious interpretation.
Technical details
Mechanism / biologySingle peptide designed to combine GLP-1 receptor agonism with amylin/calcitonin-receptor-family activity affecting appetite, satiety and glucose regulation.
Route / formulation boundaryOral and subcutaneous regimens are formulation-specific and not interchangeable.
Identity / data-quality noteUse current name Zenagamtide and retain Amycretin as an alias for search continuity.
Study / label regimen evidenceEarly human dose-ranging verified; Phase 3 ongoing. Subcutaneous early-phase studies ranged from low single-mg doses to 60 mg weekly; later Phase 2 T2D studied 0.4–40 mg weekly. See study-specific records.
Identifiers & alternate namesAmycretin · former name amycretin
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
3structured study records
3outcome records
6linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
